Bioventix: delightful as always
This highly unusual company continues to deliver excellent results and wonderful cash flow. We are also impressed with the clear explanation provided of their somewhat complicated activities; other AIM companies should take note. Read on here to find out more about this delightful company.
Bioventix (AIM:BVXP), which specialises in the area of antibodies for applications in clinical diagnostics, has announced excellent results for its financial year ending 30 June 2023.
This is a highly unusual AIM company, which we first covered in 2015, since when the shares have climbed over 350% and paid out substantial dividends as well. So what’s so unusual about this business?
Bioventix creates and manufactures high affinity sheep monoclonal antibodies…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
Previous article Next article